REGENERON PHARMACEUTICALS, INC.

REGNCIK 0000872589 · Every Form 4 filed by insiders at this issuer.

Filings

24

Latest Mar 5, 2024

Unique insiders

11

Showing

24 of 24

Page 1

Top insiders

Most active reporters at REGENERON PHARMACEUTICALS, INC.

All filings

24 Form 4 / 4-A filings, newest first

FiledInsiderTop transactionSharesPriceValue
Mar 5, 2024
RYAN ARTHUR F
Director
S19$984.45$18,705
Feb 28, 2024
STAHL NEIL
EVP Research and Development
G1,020$0.00$0
Feb 28, 2024
SING GEORGE L
Director
S500$995.00$497,500
Feb 28, 2024
LAROSA JOSEPH J
EVP General Counsel and Secret
S1,000$990.00$990,000
Feb 26, 2024
SING GEORGE L
Director
S1,000$970.00$970,000
Feb 26, 2024
LAROSA JOSEPH J
EVP General Counsel and Secret
S1,000$967.65$967,650
Feb 20, 2024
YANCOPOULOS GEORGE
Bd. Co-Chair, President & CSO · Director
F123,601$953.83$117,894,342
Feb 16, 2024
Van Plew Daniel P
EVP & General Mgr, Industrial
S4,261$940.44$4,007,215
Feb 13, 2024
Van Plew Daniel P
EVP & General Mgr, Industrial
F16,341$951.68$15,551,403
Feb 12, 2024
SING GEORGE L
Director
S500$955.00$477,500
Feb 9, 2024
LAROSA JOSEPH J
EVP General Counsel and Secret
S1,000$950.00$950,000
Feb 8, 2024
STAHL NEIL
EVP Research and Development
S3,127$950.43$2,971,995
Feb 6, 2024
STAHL NEIL
EVP Research and Development
F22,713$956.65$21,728,391
Feb 5, 2024
RYAN ARTHUR F
Director
S10$960.52$9,605
Jan 25, 2024
GOLDSTEIN JOSEPH L
Director
S2,707$950.00$2,571,650
Jan 4, 2024
Thompson Craig B.
Director
A135$0.00$0
Jan 4, 2024
LAROSA JOSEPH J
EVP General Counsel and Secret
F24,493$912.30$22,344,964
Jan 4, 2024
YANCOPOULOS GEORGE
Bd. Co-Chair, President & CSO · Director
S16,848$900.00$15,163,200
Jan 4, 2024
BROWN MICHAEL S
Director
A135$0.00$0
Jan 4, 2024
GOLDSTEIN JOSEPH L
Director
A135$0.00$0
Jan 4, 2024
SING GEORGE L
Director
A135$0.00$0
Jan 4, 2024
RYAN ARTHUR F
Director
S29$900.59$26,117
Jan 4, 2024
POON CHRISTINE A
Director
A135$0.00$0
Jan 4, 2024
COLES N ANTHONY
Director
A135$0.00$0

Showing 124 of 24

Page 1 of 1
Real-time Form 4 intelligence. Smarter insider tracking.